Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter
Advanced Clear Cell Renal Cell Carcinoma
Mayo ClinicvaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Advanced Clear Cell Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Casdatifan Arcus Biosciences, Inc. | Phase 3 | B |
Palbociclib Stephanie Berg | Phase 2 | B |
Recombinant Human Hyaluronidase SWOG Cancer Research Network | Phase 3 | B |
Volrustomig AstraZeneca | Phase 3 | B |
Tivozanib City of Hope Medical Center | Phase 3 | B |
View all 12 →
Same molecule, other indications
Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →